Quanterix stock plunges to 52-week low of $6.66 amid market challenges

Published 03/18/2025, 09:31 AM
Quanterix stock plunges to 52-week low of $6.66 amid market challenges

Quanterix Corporation (NASDAQ:QTRX), a company specializing in digital health solutions, has seen its stock price tumble to $6.66, near its 52-week low. According to InvestingPro data, the company maintains strong financial fundamentals with a current ratio of 10.07, indicating robust liquidity with assets well exceeding short-term obligations. This significant drop reflects a stark 73% decline over the past year, underscoring the intense pressures the company has faced in the market. Despite the challenging price action, InvestingPro analysis suggests the stock is currently undervalued, with analyst price targets ranging from $10 to $28. Investors have been closely monitoring Quanterix’s performance, as the stock’s downward trajectory raises questions about the company’s future prospects and the broader implications for the digital health sector. The 52-week low serves as a critical juncture for Quanterix, with stakeholders looking for strategies to stabilize and potentially reverse the negative trend. Get the complete picture with 8 additional exclusive InvestingPro Tips and comprehensive financial analysis in the Pro Research Report.

In other recent news, Quanterix Corporation reported its fourth-quarter 2024 earnings, with an earnings per share (EPS) of -$0.30, which fell short of the forecasted -$0.23. Despite this, the company’s revenue reached $35.16 million, closely aligning with expectations of $35.25 million. Revenue for the full year 2024 was $137.4 million, marking a 12% year-over-year growth. The company is also committed to a merger with Akoya Biosciences, which is expected to enhance its market capabilities, particularly in immunology and oncology. Canaccord Genuity recently revised Quanterix’s stock target to $15 from $20, while maintaining a Buy rating, citing potential challenges due to U.S. academic funding headwinds. Analysts remain optimistic about the company’s valuation and foresee factors that could stimulate double-digit revenue growth. Quanterix launched 20 new assays in 2024 and plans to introduce the SIMO-one platform in late 2025, which is anticipated to drive future growth. The company projects revenue between $140 million and $146 million for 2025, indicating a growth rate of 2-6%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.